Inflation reduction Act Lowers Prescription Drug Costs: What Medicare Members Need to no
Table of Contents
The Inflation Reduction Act (IRA), signed into law in 2022, is beginning to deliver on its promise of lower prescription drug costs for millions of Americans. The law allows Medicare to negotiate prices for some of the most expensive medications, a change expected to save Medicare members an estimated $129 per year, on average, with roughly 5.3 million people benefiting from the initial price reductions. While the major impact of these negotiations will be felt starting in 2027, some drugs are already seeing price drops.
How the Inflation Reduction act Impacts Drug Prices
For decades, Medicare was prohibited from directly negotiating drug prices with pharmaceutical companies. This meant Medicare frequently enough paid significantly more for medications than othre countries. The IRA changes this by allowing the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain high-cost drugs covered under Medicare Part D and part B. https://www.cms.gov/about-cms/what-cms-does/inflation-reduction-act
Key provisions of the IRA regarding drug pricing include:
* Negotiation: CMS will negotiate prices for a select number of high-expenditure, single-source drugs (drugs without generic or biosimilar competition). The number of drugs subject to negotiation will increase over time.
* Inflation rebates: Drug manufacturers are required to pay rebates to Medicare if they increase drug prices faster than inflation.
* $2,000 Out-of-Pocket Cap: starting in 2025, Medicare beneficiaries will have a $2,000 annual out-of-pocket limit for prescription drugs under Part D. https://www.kff.org/topic/health-care-marketplace/inflation-reduction-act-key-facts/
* Free Vaccines: The IRA eliminates cost-sharing for recommended vaccines covered under Medicare Part D.
Drugs Already Seeing Price reductions
While the bulk of the negotiated prices won’t take affect untill 2027, some pharmaceutical companies have already lowered prices in anticipation of the changes. Novo Nordisk, the manufacturer of Ozempic and Wegovy (used for type 2 diabetes and weight loss, respectively), announced price reductions in early 2024. https://www.reuters.com/business/healthcare-pharmaceutical/novo-nordisk-cuts-some-us-drug-prices-ahead-medicare-negotiations-2024-03-14/ These reductions are not a direct result of negotiation yet, but demonstrate the potential impact of the IRA on drug pricing.
What This Means for Medicare Members
The IRA represents a important step towards making prescription drugs more affordable for Medicare beneficiaries. The estimated savings of $129 per year are just the beginning. The $2,000 out-of-pocket cap, starting in 2025, will provide considerable relief for those with high medication costs.
According to the Kaiser Family Foundation, the IRA is projected to reduce government spending by $101.4 billion over ten years. https://www.kff.org/policy/health-reform/inflation-reduction-act-impact-on-drug-prices/
Looking Ahead
The implementation of the IRA is an ongoing process. CMS will continue to announce the drugs selected for negotiation in the coming years. It’s important for Medicare members to stay informed about these changes and how they may benefit.
Key Takeaways:
* The Inflation Reduction Act allows Medicare to negotiate drug prices, lowering costs for beneficiaries.
* An estimated 5.3 million Medicare members will benefit, saving an average of $129 per year.
* A $2,000 out-of-pocket cap for prescription drugs will take effect in 2025.
* Some drug manufacturers have already lowered prices in anticipation of the changes.
Frequently Asked Questions (FAQ)
Q: When will I see the full benefits of the Inflation Reduction Act?
A: The full benefits, including negotiated drug prices, will be realized starting in 2027. The $2,000 out-of-pocket cap takes effect in 2025.
Q: Will all drugs be subject to negotiation?
A: no. Initially, only a limited number of high-cost drugs without generic or biosimilar competition will be selected for negotiation. The number of drugs subject to negotiation
Keep reading